Nantahala Capital Management LLC Buys 33,504 Shares of Surrozen, Inc. $SRZN

Key Points

• Nantahala Capital Management LLC increased its stake in Surrozen, Inc. by 17.1%, acquiring an additional 33,504 shares, bringing its total ownership to 229,527 shares.
• Wall Street analysts have a consensus rating of "Buy" for Surrozen's stock, with an average target price of $38.50.

Nantahala Capital Management LLC raised its stake in shares of Surrozen, Inc. (NASDAQ:SRZN - Free Report) by 17.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 229,527 shares of the company's stock after purchasing an additional 33,504 shares during the quarter. Nantahala Capital Management LLC owned 7.00% of Surrozen worth $2,676,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in SRZN. Geode Capital Management LLC increased its holdings in shares of Surrozen by 26.1% during the 4th quarter. Geode Capital Management LLC now owns 22,391 shares of the company's stock worth $321,000 after purchasing an additional 4,630 shares during the period. Stempoint Capital LP increased its holdings in shares of Surrozen by 91.7% during the 4th quarter. Stempoint Capital LP now owns 350,573 shares of the company's stock worth $5,031,000 after purchasing an additional 167,655 shares during the period. Stonepine Capital Management LLC increased its holdings in shares of Surrozen by 24.7% during the 4th quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company's stock worth $1,969,000 after purchasing an additional 27,200 shares during the period. Trustees of Columbia University in the City of New York bought a new position in shares of Surrozen during the 4th quarter worth about $688,000. Finally, Vivo Capital LLC bought a new position in shares of Surrozen during the 1st quarter worth about $3,032,000. Institutional investors own 66.57% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $32.00 price objective on shares of Surrozen in a report on Monday, May 12th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $38.50.

Surrozen Price Performance

Shares of Surrozen stock traded down $0.25 during trading on Friday, hitting $12.20. 10,581 shares of the company's stock traded hands, compared to its average volume of 17,021. The firm's fifty day moving average price is $10.00 and its 200 day moving average price is $9.91. Surrozen, Inc. has a twelve month low of $5.90 and a twelve month high of $18.17. The company has a market cap of $104.55 million, a PE ratio of -0.85 and a beta of 0.62.

Surrozen (NASDAQ:SRZN - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.09. The business had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 274.42% and a negative return on equity of 545.43%. As a group, equities research analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.